Tysabri and Humira take very different mechanistic approaches to moderate-to-severe Crohn's disease, and they differ sharply in how they are prescribed, monitored, and accessed. Humira (adalimumab) is a subcutaneous anti-TNF biologic that is widely prescribed as a first-line biologic for Crohn's. Tysabri (natalizumab) is an integrin-blocking biologic restricted by the TOUCH program due to risk of progressive multifocal leukoencephalopathy (PML). This guide walks through the tysabri vs humira crohn's comparison.
Integrin vs Anti-TNF Mechanism
Humira binds TNF-alpha and reduces inflammation throughout the body and in the gut. Tysabri binds alpha-4 integrin, blocking lymphocyte trafficking to both gut and brain tissue. Unlike gut-selective Entyvio, which targets alpha-4-beta-7 integrin and stays limited to the gut, Tysabri's broader alpha-4 blockade affects trafficking to the central nervous system, which underlies its PML risk. The natalizumab vs adalimumab distinction is as much about safety monitoring as about efficacy.
Crohn's Efficacy
Humira's Crohn's efficacy rests on CLASSIC-1 and CHARM, which established adalimumab as effective for induction and maintenance. Tysabri's Crohn's efficacy rests on ENACT-1, ENACT-2, and ENCORE, which showed meaningful response and remission benefits over placebo. No head-to-head trial has directly compared Tysabri with Humira in Crohn's. Indirect comparisons suggest similar efficacy in biologic-experienced Crohn's patients, though the safety differences typically drive the choice.
PML Risk and TOUCH Program
Tysabri carries a black-box warning for PML, a rare but often fatal demyelinating brain disease caused by JC virus reactivation. Risk factors include prior immunosuppressant use, duration of Tysabri therapy beyond 2 years, and JC virus antibody positivity. The TOUCH program (Tysabri Outreach: Unified Commitment to Health) requires enrollment, JC virus antibody testing, routine monitoring, and prescriber/pharmacy/infusion center certification. Most gastroenterologists reserve Tysabri for Crohn's patients who have failed multiple other biologic classes and who test negative for JC virus antibodies. Humira has no such restricted access program.
Humira Safety Profile
Humira carries anti-TNF class risks including serious infections, reactivation of latent TB or hepatitis B, and a small increase in lymphoma risk. These risks are quantifiable and manageable with standard pre-treatment screening and ongoing monitoring, and they are substantially less severe than PML. For tysabri vs humira side effects, the risk-benefit equation strongly favors Humira as a first-line option for the typical Crohn's patient.
Administration and Dosing
Humira for Crohn's uses 160 mg SC on day 1, 80 mg on day 15, and then 40 mg every other week maintenance, per AbbVie's prescribing information. Humira is all-SC and can be self-administered at home. Tysabri is administered as a 300 mg IV infusion every 4 weeks at a TOUCH-certified infusion center, per Biogen's prescribing information. Tysabri requires lifelong infusions with routine TOUCH program monitoring.
Onset of Action
Both drugs produce clinically meaningful Crohn's response over similar timeframes, with response typically evident by week 8 to 12. The administration burden and safety profile differences typically drive the choice more than onset considerations.
Biosimilar Availability and Cost
Humira faces extensive biosimilar competition. Multiple adalimumab biosimilars are available and often preferred on insurance formularies. Tysabri has a biosimilar (Tyruko) approved in 2023, though real-world utilization in IBD remains low given the TOUCH program requirements apply equally to biosimilars.
Practical Access
Humira is widely available at retail pharmacies and can be shipped to patients' homes. Tysabri requires infusion at a TOUCH-certified center, limiting access for patients who live far from such centers. TOUCH program enrollment adds administrative steps at initiation and ongoing visits. For patients with complex schedules or geographic barriers, Humira's accessibility is a practical advantage.
When Tysabri Might Be Considered
For Crohn's patients who have failed multiple biologic classes (anti-TNFs, IL-12/23, gut-selective, IL-23 p19), Tysabri may be considered as a treatment option, particularly in patients who test negative for JC virus antibodies (indicating lower PML risk). This is a narrow population, and shared decision-making with a gastroenterologist experienced in refractory Crohn's is essential.
Choosing With Your GI
For a Crohn's patient deciding between Tysabri and Humira, Humira is preferred for most patients because of its established first-line role, favorable safety profile, self-administered SC dosing, and biosimilar cost options. Tysabri is a niche option reserved for patients who have exhausted other biologic classes and who test JC virus antibody negative, given its PML risk and TOUCH program restrictions. If you are considering Tysabri, ask your GI about JC virus antibody status, prior treatment history, and the specific risk-benefit rationale for choosing Tysabri over newer biologics like IL-23 p19-selective options. A log of stool frequency, urgency, abdominal pain, and any new neurological symptoms between visits is particularly important for patients on Tysabri.
This article is for educational purposes and is not medical advice. It is researched against current AGA clinical guidelines and peer-reviewed sources. Always discuss treatment decisions with your care team.